Related Experiment Video
Updated: Aug 5, 2026

Quantification of Hypopigmentation Activity In Vitro
Published on: March 6, 2019
Eltrombopag-Induced Serum Pigmentation in Severe Aplastic Anemia: A Case Report
Eva Desbrousses1, Tifenn Charbonnel2, Flavie Arbion3
1Department of Clinical Hematology, Tours University Hospital, Tours, France.
Introduction:
Severe aplastic anemia (SAA) is a bone marrow failure disorder characterized by profound pancytopenia associated with a high risk of infection and bleeding.
Case Presentation:
We report a case of a 19-year-old patient with a history of acute hepatitis who was admitted to the hospital with acquired SAA attested by 2% cellularity at bone marrow trephine biopsy. In the absence of matched sibling donor, immunosuppressive therapy with horse anti-thymocyte globulin, cyclosporine, and eltrombopag was initiated. Following centrifugation, serum obtained from blood samples addressed to the laboratory displayed a rare manifestation of brown color. Intravascular hemolysis was excluded based on normal haptoglobin and lactate dehydrogenase ranges, although bilirubin was mildly elevated. The brown staining disappeared after therapy discontinuation. Eltrombopag is a chromogenic molecule which absorbs visible light associated with serum coloration.
Conclusion:
This rare case highlights drug-induced serum pigmentation as a surprising manifestation in patients receiving eltrombopag and its normalization following drug withdrawal.